Monopar Therapeutics (NASDAQ:MNPR) Cut to “Sell” at Wall Street Zen

Wall Street Zen downgraded shares of Monopar Therapeutics (NASDAQ:MNPR) from a hold rating to a sell rating in a report published on Saturday morning,Wall Street Zen reports.

Several other brokerages have also commented on MNPR. HC Wainwright upped their price target on Monopar Therapeutics from $105.00 to $125.00 and gave the company a “buy” rating in a research note on Wednesday, July 22nd. Zacks Research downgraded Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 13th. BTIG Research raised their price objective on Monopar Therapeutics from $117.00 to $133.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Morgan Stanley restated an “overweight” rating and issued a $130.00 price objective on shares of Monopar Therapeutics in a report on Monday, August 17th. Finally, UBS Group set a $125.00 price objective on shares of Monopar Therapeutics in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $122.00.

Monopar Therapeutics Stock Performance

MNPR opened at $77.05 on Friday. Monopar Therapeutics has a one year low of $50.07 and a one year high of $124.82. The stock has a market capitalization of $517.01 million, a PE ratio of -35.51 and a beta of 1.50. The business’s 50 day moving average price is $103.65 and its 200 day moving average price is $83.85.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.64) by $0.02. As a group, equities research analysts forecast that Monopar Therapeutics will post -2.98 earnings per share for the current fiscal year.

Insider Activity at Monopar Therapeutics

In related news, Director Raymond Anderson sold 3,142 shares of Monopar Therapeutics stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total value of $351,181.34. Following the completion of the sale, the director owned 23,751 shares in the company, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher M. Starr sold 8,400 shares of the business’s stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total value of $659,400.00. Following the completion of the sale, the director directly owned 5,173 shares in the company, valued at approximately $406,080.50. The trade was a 61.89% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 44,688 shares of company stock worth $4,023,094. Company insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of MNPR. Bank of New York Mellon Corp purchased a new position in Monopar Therapeutics during the 2nd quarter valued at about $7,124,000. Walleye Capital LLC acquired a new position in Monopar Therapeutics in the 1st quarter valued at about $3,458,000. Siren L.L.C. grew its position in Monopar Therapeutics by 27.2% in the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after acquiring an additional 57,820 shares in the last quarter. Bank of America Corp DE grew its position in Monopar Therapeutics by 838.2% in the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock valued at $3,271,000 after acquiring an additional 53,336 shares in the last quarter. Finally, ADAR1 Capital Management LLC increased its stake in Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares during the period. 1.83% of the stock is currently owned by hedge funds and other institutional investors.

About Monopar Therapeutics

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.